Getting your player ready...
WASHINGTON — Federal health regulators on Friday approved a potential blockbuster diabetes drug from Bristol- Myers Squibb Co. and partner Astrazeneca PLC.
The Food and Drug Administration said it approved the companies’ drug Onglyza to reduce blood sugar levels in patients with Type 2 diabetes, which affects 24 million people in the U.S.
